This human FXN YAC transgenic mouse model has the mouse frataxin knockout allele (Fxn-) and the human FXN YAC transgene from founder YG8 (carrying two tandem copies of the human FXN gene with ~82 and ~190 GAA trinucleotide sequence repeats). Mice homozygous for the knockout and hemizygous for the YG8 transgene, called YG8R mice, are rescued from knockout lethality and have transgene expression that models the phenotype of Friedreich's Ataxia (FRDA).
Mark A Pook, Brunel University
This strain is maintained heterozygous for the targeted mutation and hemizygous for the transgene.
Importation of this model was supported by the Friedreich's Ataxia Research Alliance (FARA).
The YG8 transgenic founder line carries two tandem copies of the human FXN gene with ~82 and ~190 GAA trinucleotide sequence repeats. Mice that are heterozygous for the Fxn- knockout allele and hemizygous for the YG8 transgene are viable and fertile. High levels of human FXN gene product (mRNA or protein) are detected by RT-PCR and Western blot analysis. Approximately 40-50% of the endogenous mouse Fxn gene product (protein) is detected by Western blot analysis in mice heterozygous for the Fxn- knockout allele alone. Mice homozygous for the Fxn- knockout allele and hemizygous for the YG8 transgene, called YG8R mice, are rescued from knockout lethality and have transgene expression that results in an age-dependent, tissue-specific expansion of the GAA repeat, with expansion accumulation observed in the CNS (particularly cerebellum), similar to the human pathology of Friedreich's Ataxia. The GAA triplet repeats exhibit intergenerational instability.
In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
It should be noted that the YAC transgenic FRDA mouse models available from The Jackson Laboratory (YG22R, YG8R and YG8sR) may have different GAA repeat sizes than the animals used in the publications described below.
Publicationsfrom Dr. Mark A. Pook (Brunel University London) in 2014-2015 examine the correlation between the FRDA-like pathological phenotype and frataxin-deficiency in the YAC transgenic FRDA mouse models YG22R (two copies of the FRDA transgene; 190 GAA repeats expanded to ~170-260), YG8R (two copies of the FRDA transgene; 90-190 GAA repeats expanded to ~120-220) and YG8sR (a contraction of the transgene to a single copy; ~120-150 GAA repeats) compared to Y47R control mice (one copy of the FRDA transgene with a stable 9 GAA repeat) and C57BL6/J wildtype mice. The results described below are all in comparison to control mice.
The three YAC transgenic FRDA mouse models (YG8R, YG22R and YG8sR) had a progressive decrease in the motor coordination; the degree of impairment was most significant in YG8R mice. All three models exhibited GAA repeat somatic instability in the brain, cerebellum and liver, as well as exhibited glucose intolerance and insulin hypersensitivity. The greatest FXN deficiency of the three models tested was in YG8sR. Expression levels of the transgenes in various tissues are reported in the Pook publications.
These double mutant mice, heterozygous for the targeted mutation and hemizygous for the transgene, were generated by crossing transgenic mice (founder line YG8) with Fxntm1Mkn targeted mutant mice.
Drs. Michel Koenig and Helene Puccio generated the Fxn targeted mutation allele by disrupting exon 4 and flanking sequences with a loxP site flanked PGK-neo cassette. The construct was electroporated into 129/Sv derived embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts. The resulting chimeric animals were crossed to C57BL/6J mice, and then backcrossed to C57BL/6J for five generations.
The transgenic construct consisting of a 370kb YAC insert that includes the entire human FXN gene with GAA triplet repeat sequences, was injected into fertilized CBA X C57BL/6 hybrid fertilized oocytes. Founder line YG8 was established, carrying 2 tandem copies of the human FXN gene with GAA trinucleotide sequence repeats as low as 122 and as high as 207. Founder animals were bred to wildtype C57BL/6J mice for five generations.
The two lines were then crossed to generate the double mutant. The Donating Investigator breeds mice that are heterozygous for the Fxntm1Mkn targeted mutation and hemizygous for the YG8 transgene to mice that are heterozygous for the Fxntm1Mkn targeted mutation to obtain mice homozygous for the Fxntm1Mkn targeted mutation and hemizygous for the YG8 transgene.
SNP (single nucleotide polymorphism) analysis performed by The Jackson Laboratory revealed that the mice originally imported were on a mixed genetic background. The mixed genetic background mice were then backcrossed to C57BL/6J for five generations.
|Expressed Gene||Fxn, frataxin, mouse, laboratory|
|Site of Expression|
|Expressed Gene||FXN, frataxin, human|
|Site of Expression|
|Allele Name||targeted mutation 1, Michel Koenig|
|Allele Type||Targeted (Null/Knockout)|
|Allele Synonym(s)||Frda-; Frdadel4|
|Gene Symbol and Name||Fxn, frataxin|
|Gene Synonym(s)||CyaY; FA; FARR; FRDA; Frda; Frda; Friedreich ataxia; RGD1565754; X25|
|Expressed Gene||Fxn, frataxin, mouse, laboratory|
|Strain of Origin||129/Sv|
|Molecular Note||A loxP-flanked PGK-neomycin resistance cassette replaced a genomic DNA fragment containing exon 4, which is highly conserved and often mutated in humans. An additional line was also produced in which the loxP flanked neomycin cassette was removed by Cre mediated recombination, but no distinction was made between these alleles in the original reference. From J:90098: The presence of a human FRDA transgene in hemizygous form in a Frdatm1Mkn homozygous null background rescues the embryonic lethal phenotype and complements for the loss of endogenous mouse frataxin.|
|Allele Name||transgene insertion YG8, Mark A Pook|
|Allele Type||Transgenic (Humanized sequence, Inserted expressed sequence)|
|Gene Symbol and Name||Tg(FXN)YG8Pook, transgene insertion YG8, Mark A Pook|
|Promoter||FXN, frataxin, human|
|Expressed Gene||FXN, frataxin, human|
|Strain of Origin||CBA x C57BL/6|
|General Note||Line YG22 exhibits slightly greater age-related repeat instability, with a bias toward repeat expansion.|
|Molecular Note||The transgenic construct consists of a 370kb YAC insert that includes the entire human FXN gene with GAA triplet repeat sequences, and was injected into fertilized CBA X C57BL/6 hybrid fertilized oocytes. Founder line YG8 was established, carrying 2 tandem copies of the human FXN gene with two GAA trinucleotide repeat sequences of 82 and 190 repeats. This line displayed a transmission rate of 52% to offspring.|
When maintaining a live colony, these mice can be bred as heterozygotes for the targeted mutation and hemizygotes for the transgene.
When using the B6.Cg-Fxntm1Mkn Tg(FXN)YG8Pook/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #012253 in your Materials and Methods section.
|Heterozygous or wild-type for Fxn<tm1Mkn> , Hemizygous or Non Carrier for Tg(FXN)YG8Pook|
We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.
|Frozen Mouse Embryo||$2,595.00 per straw or vial|
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.
MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.
Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.